United States: Cannabis Group Weekly Alert - Week Of July 16, 2019

In this week’s edition:

  • FDA expedites its efforts to develop rules for CBD and plans to report on its progress by late summer/early fall.
  • Florida appellate court strikes down the state’s vertically integrated business model and current cap on medical cannabis operators.
  • Iowa takes hard stance against CBD, stating that all products containing the chemical compound are illegal in the state, with the exception of FDA-approved drugs and Iowa’s medical CBD program.
  • Ohio regulator claims two multi-state operators violated the state’s rules by inappropriately transferring ownership interests and misrepresenting information in license applications.
  • Several well-known individuals recently entered the cannabis industry, including: Jay-Z (serving as Caliva’s chief brand strategist); former Chicago Tribune CEO Tony Hunter (joined Revolution Enterprises); former Home Depot CEO Bob Nardelli (as strategic advisor to GrowGeneration Corp.); and former Kellogg CFO Fareed Kahn (as Surterra Wellness’ next finance chief)


A group of experts testified before the House Subcommittee on Crime, Terrorism, and Homeland Security in favor of federal legislation to allow for the legal sale of cannabis. Rep. Steve Cohen (D-TN) described the Capitol Hill hearing, entitled “ Marijuana Laws in America: Racial Justice and the Need for Reform,” as “historic” and Rep. Ted Lieu (D-CA) expressed optimism for the bipartisan support for reform, stating “I believe we can get this done.” However, lawmakers and witnesses differed on how to end federal prohibition with some favoring an incremental approach and others calling for full de-scheduling and comprehensive federal reform.

House consideration of the  SAFE Banking Act may be delayed until after the August recess.  David Quam, Dentons Counsel and member of the public policy team, reports that earlier plans to move the SAFE Banking Act in early July were put off after the House included similar language in its Financial Services Appropriations bill.  The House is scheduled to adjourn the end of next week and return September 9.

A new Marijuana Justice Coalition has been formed to advocate for the inclusion of social equity provisions in cannabis legalization legislation. Leading civil rights and criminal justice reform group members include the ACLU, Center for Law and Social Policy, Drug Policy Alliance, Human Rights Watch, Immigrant Legal Resource Center, Lawyers’ Committee for Civil Rights Under Law, Leadership Conference on Civil & Human Rights, NORML and Students for Sensible Drug Policy.  The Coalition calls for measures that focus on investing in communities disproportionately harmed by prohibition, encouraging participation by impacted individuals, expunging the records of those with prior convictions, and ensuring that work in a legal market does not impact citizenship applications.

The US government plans to grow 2,000 kilograms of cannabis at the University of Mississippi for research purposes,  the government’s largest crop in the past five years. The University of Mississippi is the only establishment authorized by the federal government to cultivate cannabis for research purposes.  More than two dozen grower applications are pending before the US Drug Enforcement Administration.  The National Institute on Drug Abuse states that cannabis demand for research has not increased significantly and that the number of researchers receiving government cannabis has ranged from eight to 21 since 2010.

Rep. Alexandria Ocasio-Cortez (D-NY) and Sen. Kamala Harris (D-CA) introduced companion bills that would prohibit public housing providers from turning away people with low-level drug convictions and inquiring about their current drug and alcohol usage.  The legislation would repeal the US Department of Housing and Urban Development’s (HUD’s) one-strike policy, which allows public housing owners to evict tenants for engaging in illicit drug use or other crimes.

The US House of Representatives approved an amendment to end a current Department of Veterans Affairs policy that denies home loan applications to military veterans who have worked in the cannabis industry.


Alaska regulators wrestled with how to interpret regulations regarding on-site consumption, rejecting the first application for on-site consumption because of concerns as to whether the site was located in a “freestanding” building.  While the applicant was “all by itself in the middle of a field,” it was not the only business at the address.

California’s Legislature has adjourned for summer recess to reconvene on August 12.  A number of cannabis and CBD related bills are still pending, including A.B.228.  In the past week, A.B. 127 was enacted, allowing persons under the influence of alcohol or drugs to operate a vehicle under the supervision of the California Highway Patrol for purposes of research on impaired driving.

Florida’s appellate court struck down the state’s vertically integrated business model and current cap on the number of medical cannabis operators in the state. The First District Court of Appeal’s decision holds that the current system requiring vertical integration is unconstitutional and the limit on the number of licenses available is unreasonable. In 2016, 71 percent of Floridians voted to amend the state’s constitution and legalize medical cannabis. The 2017 statute implementing the medical cannabis model was found to impermissibly amend the constitutional definition of “medical marijuana treatment centers” to require vertical integration.  Florigrown sued the Department of Health, which regulates cannabis in Florida, after being denied a license. The appellate judges, stating that it is not in public interest to immediately open up the licensing model, directed the Department of Health to come up with a different regulatory structure that would allow for a reasonable number of licenses.

Hawai`i decriminalized the possession of three grams or less of cannabis, effective January 11, 2020. Governor David Ige (D) vetoed separate bills to allow inter-island medical cannabis transportation and to create a hemp licensing program.  Of the former, Gov. Ige stated that because cannabis remains illegal at the federal level—and “airspace and certain areas of water fall within the exclusive jurisdiction of the federal government”—that enacting the bill could lead travelers to “erroneously believe they are immune from federal prosecution.” On the latter, he stated that he wants to make sure that any hemp laws passed in Hawaii are aligned with the still-unpublished USDA rules.

Ohio’s Board of Pharmacy claims that two medical cannabis companies violated state rules: Greenleaf Apothecaries LLC (dba The Botanist) transferred ownership to Acreage without state approval and Harvest of Ohio LLC inaccurately represented on its application that is an “economically disadvantaged group.” Acreage Holdings announced a management agreement with Greenleaf Apothecaries in December 2018 and Greenleaf agreed to sell all interests to Acreage when allowed by the state.

Oklahoma’s Medical Marijuana Authority has announced that it is taking steps to implement state’s medical cannabis program, including rule promulgation, information technology changes, application developments and operational planning. The changes will be implemented through November with permanent rules expected in 2020.

Pennsylvania has added, effective July 21, anxiety and Tourette’s syndrome to its list of ailments that qualify for treatment with medical cannabis.

Rhode Island increased the number of possible medical cannabis compassion centers from three to nine, while also increasing the licensing fee to $500,000 per center.


FDA Acting Chief Information Officer Amy Abernethy tweeted that the “FDA is expediting its work to address the many questions about cannabidiol (CBD),” reflecting that it is an important issue with many stakeholders, including American hemp farmers. She said the FDA is “enthusiastic about research into therapeutic benefits of CBD products but also need to balance safety.” The FDA plans to report on its progress by the end of summer or early fall. 

Iowa’s Attorney General’s Office released guidance clarifying that under the state’s current law, any product containing cannabidiol is illegal with the exception of FDA-approved medications and Iowa’s medical CBD program.  When the Iowa Hemp Act becomes fully effective, “CBD products containing no more than 0.3% THC will no longer be controlled substances under Iowa law.” The Attorney General’s Office cautioned that “this does not mean that all such products will become legal.”

South Carolina Department of Pesticide Regulation approved a list of pesticides for use on hemp crops.  All of the approved pesticides are classified as 25(b) pesticides, meaning the US Environmental Protection Agency considers them minimum-risk pesticides. To date, the SC Department of Agriculture has approved 114 growers under the state’s hemp-farming program for 2019.

Guam Customs and Quarantine Agency seized air cargo shipments of CBD products and is awaiting further direction from the US Food and Drug Administration regarding disposition of the goods. Customs seized the goods because of concerns with labeling compliance.

American Eagle will start selling, in October, CBD-infused personal care products developed and supplied by Green Growth Brands. American Eagle views CBD as the next big trend in lifestyle focused on health, appealing directly to its mainly millennial audience.


CannTrust Holdings Inc. announced that it has ceased sale and shipment of all cannabis products following Health Canada inspections that revealed the existence of several unlicensed grow rooms at an Ontario facility.  Health Canada seized more than five metric tons of CannTrust’s inventory.

Costa Rica’s Ministry of Health is considering allowing medical cannabis production operations in its free trade zone industrial parks. Colombia is similarly considering whether to allow the exportation of flower into free trade zones for further processing.

Czech Republic lawmakers have moved legislation forward that would allow insurance to cover 90 percent of medical cannabis costs. The bill has been approved by the Chamber of Deputies and now must be approved by the Senate.

French officials approve medical cannabis trials to study the therapeutic effects of cannabis in patients who suffer from certain forms of treatment resistant epilepsy, neuropathic pain (resulting from nerve damage), multiple sclerosis or other central nervous system pathologies.

Israel’s Health Ministry announced steps to make it easier for medical cannabis consumers to access their medications, including a plan to supervise and fix pricing to keep costs low.  Some patients are concerned that the steps will not alleviate the issues, which are caused primarily by an “extreme shortage” in supply.

New Zealand’s Ministry of Health released draft medical cannabis rules, following the passage of a law last year that broadened the legality of cannabis for medicinal purposes. A Medicinal Cannabis Agency would be set up by the first quarter of 2020 to oversee the regulatory scheme.


Jay-Z has entered the cannabis industry by partnering with Caliva as a chief brand strategist. He will also focus on advocacy and job training programs to empower formerly incarcerated individuals to enter the legal cannabis industry.

MJBizDaily is working with cannabis data analytics company Headset to give MJBizDaily access to retail data from the cannabis industries in the US and Canada.  MJBizDaily and Headset will work together to develop exclusive content as part of their Annual Marijuana Business Factbook

Surterra Wellness hired former Kellogg Company executive Fareed Khan.  Khan brings experience as the multinational food brand’s chief financial officer, in which position he helped drive the adoption of a new corporate strategy that included revitalizing key brands and transforming the company’s portfolio through mergers and acquisitions. Surterra has vertical operations in Florida, Texas, Nevada and Massachusetts. 

GrowGeneration Corp., an owner and operator of specialty retail hydroponic and organic gardening stores, has appointed Bob Nardelli, a former chief executive officer of Home Depot, as a senior strategic advisor.

Anonymous Analytics, a “faction” of the global Anonymous activist movement, has initiated a buy rating on Turning Point Brands Inc (TPB.N). Turning Point Brands sells periphery products, including rolling papers, chewing tobacco and vapes, and has a network of 1.5 million online customers and 155,000 stores.

Revolution Enterprises, a multi-state operator in Illinois, Florida and Arkansas, has named Tony Hunter, former chief executive officer of the Chicago Tribune, chairman of the board.


The National Institutes of Health is funding a study to identify gut-brain endocannabinoid signaling pathways that control feed behavior and become impaired in obesity.

An assistant professor at the University of Saskatchewan has secured funding for preclinical research to explore the effects of cannabinoids on natural neurotransmitters to regulate wakefulness and appetite. The Natural Sciences and Engineering Research Council (NSERC) is funding the study for five years. NSERC is also funding research into other cannabis-related areas, including the chemistry of cannabis and its detection, improving growing techniques, and the impact of cannabis on human health and veterinary medicine. 

About Dentons

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions